A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II
NCT ID: NCT05055258
Last Updated: 2023-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
33 participants
INTERVENTIONAL
2021-09-27
2022-10-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
NCT05505916
C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
NCT01005888
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
NCT00438815
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
NCT00262301
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
NCT06361537
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
300 mg KVD824
300 mg KVD824 twice a day for 12 weeks
KVD824
KVD824 300 mg Modified-Release Tablets
600 mg KVD824
Two 300 mg KVD824 tablets twice a day for 12 weeks
KVD824
KVD824 300 mg Modified-Release Tablets
900 mg KVD824
Three 300 mg KVD824 tablets twice a day for 12 weeks
KVD824
KVD824 300 mg Modified-Release Tablets
Placebo to KVD824
One, two or three placebo tablets to be taken twice a day for 12 weeks
Placebo to KVD824
Placebo to KVD824 300 mg Modified-Release Tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KVD824
KVD824 300 mg Modified-Release Tablets
Placebo to KVD824
Placebo to KVD824 300 mg Modified-Release Tablets
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Confirmed diagnosis of HAE type I or II at any time in the medical history:
1. Documented clinical history consistent with HAE (subcutaneous or mucosal, nonpruritic swelling episodes without accompanying urticaria) AND EITHER
2. Diagnostic testing results obtained prior to randomization that confirm HAE Type I or II: C1-INH functional level \<40% of the normal level. Subjects with functional C1-INH level 40-50% of the normal level may be enrolled if they also have a C4 level below the normal range. Testing may be obtained from central or local laboratories or obtained from documented historical testing results. Subjects may be restested at anytime prior to randomization if results are incongruent with clinical history or believed by the Investigator to be confounded by recent prophylactic or therapeutic C1 INH use, OR
3. Documented genetic results that confirm known mutations for HAE Type I or II.
3. Subject has access to and ability to use conventional treatment for HAE attacks.
4. Subject is willing to cease any current medications being taken for HAE prophylaxis and Investigator determines that doing so would not place the subject at any undue safety risk.
5. Subject's last dose of attenuated androgens was at least 28 days prior to first dose of IMP.
6. During the Run-in Period subject meets one of the following criteria:
1. Two Investigator-confirmed attacks in the first 4-week period.
2. Three Investigator-confirmed attacks in ≤8 weeks.
7. Subjects who are fertile and heterosexually active must adhere to contraception requirements throughout the trial as follows:
a) Female subjects must agree to use at least one highly effective contraception method from the Screening Visit until the end of the trial. Highly effective methods of contraception include: i) Progestogen-only hormonal contraception associated with inhibition of ovulation: oral/injectable/implantable (hormonal contraception that contains estrogen including ethinylestradiol is excluded per Exclusion 4).
ii) Intrauterine device (IUD). iii) Intrauterine hormone-releasing system (IUS). iv) Bilateral tubal occlusion. v) Vasectomized partner (provided that the partner is the sole sexual partner of the female subject of childbearing potential and that the vasectomized partner has received medical assessment of surgical success).
b) Male subjects with a female partner of childbearing potential must agree to use condoms for the entire Treatment Period AND for 90 days following the final dose of investigational medicinal product (IMP). Female partners are encouraged to use contraception as outlined in Inclusion 7a) from the Screening Visit until the end of the trial. Hormonal contraception that contains estrogen including ethinylestradiol is acceptable for the female partner.
8. Subjects who are not fertile or not sexually active, as defined below, do not require contraception.
1. Subjects who refrain from heterosexual intercourse during the trial if the reliability of the heterosexual abstinence has been evaluated in relation to the duration of the clinical trial and is the preferred and usual lifestyle of the subject.
2. Male subjects who are surgically sterile (e.g. vasectomized with medical assessment of surgical success).
3. Female subjects who are surgically sterile (e.g. status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post menopausal for at least 12 months.
9. Subjects must be able to swallow trial tablets whole.
10. Subjects assessed by the Investigator must be able to appropriately receive and store IMP, and be able to read, understand, and complete the eDiary.
11. Investigator believes that the subject is willing and able to adhere to all protocol requirements.
12. Subject provides signed informed consent and is willing and capable of complying with trial requirements and procedures.
Exclusion Criteria
2. A clinically significant history of poor response to C1-INH therapy or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator.
3. Use of angiotensin converting enzyme (ACE) inhibitors after the Screening Visit or within 7 days prior to randomization.
4. Any estrogen containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) after the Screening Visit or within 7 days prior to randomization.
5. Use of narrow therapeutic index drugs metabolized by CYP3A4 or CYP2C9 or transported by OAT1, OCT2, and OATP1B1, starting at screening, as determined by the Investigator.
6. Use of strong CYP3A4 inhibitors and inducers during participation in the trial, starting at the Screening Visit.
Note: These medications include but are not limited to the following:
Inhibitors: boceprevir, clarithromycin, cobicistat, dasabuvir, denoprevir, elvitegravir, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, and voriconazole.
Inducers: apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort.
7. Inadequate organ function, including but not limited to;
1. Alanine aminotransferase (ALT) \> 2x Upper limit of Normal (ULN).
2. Aspartate aminotransferase (AST) \> 2x ULN.
3. Bilirubin direct \> 1.25x ULN.
4. International normalized ratio (INR) \> 1.2.
5. Clinically significant hepatic impairment defined as a Child-Pugh B or C.
6. Estimated glomerular filtration rate (eGFR) \<60 mL/min.
8. Any clinically significant comorbidity or systemic dysfunction that in the opinion of the Investigator would jeopardize the safety of the subject by participating in the trial.
9. History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator.
10. Known hypersensitivity to KVD824 or placebo or to any of the excipients.
11. Any prior use of any gene therapy treatment for HAE.
12. Participation in any interventional investigational clinical trial, including an investigational COVID-19 vaccine trial, within 4 weeks of the last dosing of investigational drug prior to screening.
13. Any pregnant or breastfeeding subject.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KalVista Pharmaceuticals, Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
KalVista Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KalVista Investigative Site
Birmingham, Alabama, United States
KalVista Investigative Site
Scottsdale, Arizona, United States
KalVista Investigative Site
La Jolla, California, United States
KalVista Investigative Site
Santa Monica, California, United States
KalVista Investigative Site
Centennial, Colorado, United States
KalVista Investigative Site
Tampa, Florida, United States
KalVista Investigative Site
Chevy Chase, Maryland, United States
KalVista Investigative Site
Boston, Massachusetts, United States
KalVista Investigative Site
St Louis, Missouri, United States
KalVista Investigative Site
Cincinnati, Ohio, United States
KalVista Investigative Site
Hershey, Pennsylvania, United States
KalVista Investigative Site
Dallas, Texas, United States
KalVista Investigative Site
Spokane, Washington, United States
KalVista Investigative Site
Campbelltown, New South Wales, Australia
KalVista Investigative Site
Sofia, , Bulgaria
KalVista Investigative Site
North York, Ontario, Canada
KalVista Investigative Site
Brno, , Czechia
KalVista Investigative Site
Prague, , Czechia
KalVista Investigative Site
Grenoble, , France
KalVista Investigative Site
Paris, , France
KalVista Investigative Site
Mainz, Rhineland-Palatinate, Germany
KalVista Investigative Site
Berlin, , Germany
KalVista Investigative Site
Frankfurt am Main, , Germany
KalVista Investigative Site
Budapest, , Hungary
KalVista Investigative Site
Milan, , Italy
KalVista Investigative Site
Padua, , Italy
KalVista Investigative Site
Grafton, Auckland, New Zealand
KalVista Investigative Site
Skopje, , North Macedonia
KalVista Investigative Site
San Juan, , Puerto Rico
KalVista Investigative Site
Birmingham, , United Kingdom
KalVista Investigative Site
Leeds, , United Kingdom
KalVista Investigative Site
London, , United Kingdom
KalVista Investigative Site
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KVD824-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.